Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

Iris de Weerdt, MD, Tom Hofland, MSc, Johan Dobber, Julie Dubois, Eric Eldering, PhD, Mehrdad Mobasher, MD MPH, Fransien Croon-de Boer, Mels Hoogendoorn, MD PhD, Gerjo A. Velders, PhD MD, Marjolein van der Klift, Mark-David Levin, MD PhD, Sabina Kersting, MDPhD, Sanne Tonino, MD PhD, Arnon P. Kater, MD

Blood (2018) 132 (Supplement 1): 1860.

https://doi.org/10.1182/blood-2018-99-116283

Published: 2018

Journal Articles

Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification

Doreen te Raa, Perry Moerland, Alexander Leeksma, Ingrid Derks, Martin Loden, Veronika Navrkalova, Martin Trbusek, PhD, Dieuwertje Luijks, Thorsten Zenz, MD, Anna Skowronska, PhD, Tatjana Stankovic, Mels Hoogendoorn, MD PhD, Marinus H. J. van Oers, Eric Eldering, PhD, Arnon P. Kater, MD PhD

Blood (2015) 126 (23): 2918.

https://doi.org/10.1182/blood.V126.23.2918.2918

Published: 2015

Journal Articles

Impact of Radiotherapy and Rituximab on Outcome of Stage I(E) Diffuse Large B-Cell Lymphoma

Marcel Nijland, MD, Karin Boslooper, MD, Anke Van den Berg, PhD, Hanneke C. Kluin-Nelemans, MD PhD, Peter Joosten, MD, Huib Storm, MD PhD, Robby Kibbelaar, MD PhD, Gustaaf van Imhoff, MD PhD, Mels Hoogendoorn, MD PhD

Blood (2015) 126 (23): 1503.

https://doi.org/10.1182/blood.V126.23.1503.1503

Published: 2015

Journal Articles

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Pieternella J Lugtenburg, MD PhD, Josée M Zijlstra, MD, Jeanette K Doorduijn, MD PhD, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD PhD, Mels Hoogendoorn, MD PhD, Henriette W Berenschot, MD, Aart Beeker, MD, Fransje Valster, MD, Harry C. Schouten, MD PhD, Marleen Luten, MSc, Henk Hofwegen, Dana A Chitu, PhD, Rolf E Brouwer, MD PhD, Gustaaf W van Imhoff, MD PhD

Blood (2015) 126 (23): 2707.

https://doi.org/10.1182/blood.V126.23.2707.2707

Published: 2015

Journal Articles

Overall Survival Patterns in Patients with Multiple Myeloma in the Era of Novel Agents and the Role of Initial Clinical Presentation and Comorbidities: A Population-Based Study

Berdien Oortgiesen, Eric N. van Roon, PharmD, PhD, Peter Joosten, MD, Robby Kibbelaar, MD PhD, Huib Storm, PhD, Sjoerd Hovenga, MDPhD, Bas P Van Rees, MD PhD, Gerhard Woolthuis, MD, Nic J.G.M. Veeger, PhD, Mels Hoogendoorn, MD PhD

Blood (2014) 124 (21): 2136.

https://doi.org/10.1182/blood.V124.21.2136.2136

Published: 2014

Journal Articles

Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study

Esther GM Waal de, MD, Linda Munck de, Gerhard Woolthuis, MD, Annet velden Van Der, MD, Yvonne Tromp, MD, Mels Hoogendoorn, MD PhD, Edo Vellenga, MD PhD, Sjoerd Hovenga, MDPhD

Blood (2014) 124 (21): 4733.

https://doi.org/10.1182/blood.V124.21.4733.4733

Published: 2014

Journal Articles

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Michel Van Gelder, PhD, MD, Wendim Ghidey, Martine ED Chamuleau, MD, Jan Cornelissen, MD, PhD, Eefke J Petersen, MD PhD, Simon M. G. J. Daenen, Pierre Zachee, MD, PhD, Mels Hoogendoorn, MD, PhD, Aart Beker, MD, Gert Jan Timmers, MD, PhD, Arnon P. Kater, MD PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2013) 122 (21): 2883.

https://doi.org/10.1182/blood.V122.21.2883.2883

Published: 2013

Journal Articles

Prognostic Importance of Comorbidity in a Population-Based Analysis of Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

André Wieringa, PharmD, Eric N. van Roon, PharmD, PhD, Peter Joosten, MD, Tim Beerden, B.Sc, Huib Storm, PhD, Robby Kibbelaar, MD, PhD, Hanneke C. Kluin-Nelemans, Nic J.G.M. Veeger, PhD, Mels Hoogendoorn, MD, PhD

Blood (2012) 120 (21): 3656.

https://doi.org/10.1182/blood.V120.21.3656.3656

Published: 2012

Journal Articles

Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study

Hedwig M Blommestein, Djamila E Issa, MD, Marjolein Pompen, PhD, Cédric Révil, Mels Hoogendoorn, MD, PhD, Peter Joosten, MD, Sonja Zweegman, MD, PhD, Peter C. Huijgens, MD, PhD, Carin A. Uyl-de Groot, PhD

Blood (2012) 120 (21): 4277.

https://doi.org/10.1182/blood.V120.21.4277.4277

Published: 2012

Journal Articles

A Significant Better Two Year Survival in the Very Elderly Patients with a Diffuse Large B-Cell Lymphoma (DLBCL) Who Did Complete Standard Therapy: A Population-Based Cohort Study On Treatment, Toxicity and Outcome.

Karin Boslooper, Peter Joosten, MD, Nic J.G.M. Veeger, PhD, Robby Kibbelaar, MD, PhD, Eric van Roon, Sjoerd Hovenga, Gerhard Woolthuis, MD, Hanneke C. Kluin-Nelemans, Mels Hoogendoorn, MD, PhD

Blood (2012) 120 (21): 2642.

https://doi.org/10.1182/blood.V120.21.2642.2642

Published: 2012

Journal Articles

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Pieternella J Lugtenburg, MD, PhD, Josée M Zijlstra, MD, PhD, Jeanette K Doorduijn, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD, PhD, Mels Hoogendoorn, MD, PhD, Henriette W Berenschot, MD, PhD, Aart Beeker, MD, Fransje A Valster, MD, Harry C Schouten, MD, PhD, Marleen Luten, MSc, Dana A Chitu, Rolf E Brouwer, MD, PhD, Gustaaf W van Imhoff, MD, PhD

Blood (2012) 120 (21): 2729.

https://doi.org/10.1182/blood.V120.21.2729.2729

Published: 2012

NARROW

First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification

Impact of Radiotherapy and Rituximab on Outcome of Stage I(E) Diffuse Large B-Cell Lymphoma

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Overall Survival Patterns in Patients with Multiple Myeloma in the Era of Novel Agents and the Role of Initial Clinical Presentation and Comorbidities: A Population-Based Study

Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Prognostic Importance of Comorbidity in a Population-Based Analysis of Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study

A Significant Better Two Year Survival in the Very Elderly Patients with a Diffuse Large B-Cell Lymphoma (DLBCL) Who Did Complete Standard Therapy: A Population-Based Cohort Study On Treatment, Toxicity and Outcome.

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only